Generation of a replication-competent simian-human immunodeficiency virus, the neutralization sensitivity of which can be enhanced in the presence of a small-molecule CD4 mimic

Journal of General Virology

Volumn 94, Issue PART 12, 2013, Pages 2710-2716

  Otsuki, Hiroyuki ^a   Hishiki, Takayuki ^a   Miura, Tomoyuki ^a   Hashimoto, Chie ^b   Narumi, Tetsuo ^b   Tamamura, Hirokazu ^b   Yoshimura, Kazuhisa ^c   Matsushita, Shuzo ^d   Igarashi, Tatsuhiko ^a  

^a KYOTO UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; DNA FRAGMENT; IMMUNOGLOBULIN; SMALL MOLECULE TRANSPORT AGENT; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS RNA; YYA 021;

ANIMAL CELL; ANTIBODY RESPONSE; ARTICLE; CLADISTICS; CONTROLLED STUDY; EXPERIMENTAL INFECTION; HOMOLOGOUS RECOMBINATION; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REPRODUCTION; RHESUS MONKEY; SENSITIVITY ANALYSIS; SIMIAN; SIMIAN VIRUS; VIRUS ENVELOPE; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS REPLICATION; VIRUS RESISTANCE;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIGENS, CD4; HIV ANTIBODIES; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MACACA MULATTA; MOLECULAR MIMICRY; NEUTRALIZATION TESTS; RECEPTORS, CCR5; RECOMBINATION, GENETIC; RNA, VIRAL; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION;

EID: 84887553623     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.055590-0     Document Type: Article

References (32)

1. Davis, K. L., Bibollet-Ruche, F., Li, H., Decker, J. M., Kutsch, O., Morris, L., Salomon, A., Pinter, A., Hoxie, J. A. & other authors (2009a). Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. J Virol 83, 1240-1259.
2. Davis, K. L., Gray, E. S., Moore, P. L., Decker, J. M., Salomon, A., Montefiori, D. C., Graham, B. S., Keefer, M. C., Pinter, A. & other authors (2009b). High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. Virology 387, 414-426.
3. Decker, J. M., Bibollet-Ruche, F., Wei, X., Wang, S., Levy, D. N., Wang, W., Delaporte, E., Peeters, M., Derdeyn, C. A. & other authors (2005). Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med 201, 1407-1419.
4. Eda, Y., Takizawa, M., Murakami, T., Maeda, H., Kimachi, K., Yonemura, H., Koyanagi, S., Shiosaki, K., Higuchi, H. & other authors (2006). Sequential immunization with V3 peptides from primary human immunodeficiency virus type 1 produces crossneutralizing antibodies against primary isolates with a matching narrow-neutralization sequence motif. J Virol 80, 5552-5562.
5. Fujita, Y., Otsuki, H., Watanabe, Y., Yasui, M., Kobayashi, T., Miura, T. & Igarashi, T. (2013). Generation of a replication-competent chimeric simian-human immunodeficiency virus carrying env from subtype C clinical isolate through intracellular homologous recombination. Virology 436, 100-111.
6. Gray, E. S., Moore, P. L., Choge, I. A., Decker, J. M., Bibollet-Ruche, F., Li, H., Leseka, N., Treurnicht, F., Mlisana, K. & other authors (2007). Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J Virol 81, 6187-6196.
7. Igarashi, T., Endo, Y., Englund, G., Sadjadpour, R., Matano, T., Buckler, C., Buckler-White, A., Plishka, R., Theodore, T. & other authors (1999). Emergence of a highly pathogenic simian/human immunodeficiency virus in a rhesus macaque treated with anti-CD8 mAb during a primary infection with a nonpathogenic virus. Proc Natl Acad Sci U S A 96, 14049-14054.
8. Kong, L. & Sattentau, Q. J. (2012). Antigenicity and immunogenicity in HIV-1 antibody-based vaccine design. J AIDS Clin Res S8, 3.
9. Kwong, P. D. & Mascola, J. R. (2012). Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 37, 412-425.
10. Landau, N. R., Page, K. A. & Littman, D. R. (1991). Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range. J Virol 65, 162-169.
11. Li, M., Gao, F., Mascola, J. R., Stamatatos, L., Polonis, V. R., Koutsoukos, M., Voss, G., Goepfert, P., Gilbert, P. & other authors (2005). Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79, 10108-10125.
12. Lusso, P., Earl, P. L., Sironi, F., Santoro, F., Ripamonti, C., Scarlatti, G., Longhi, R., Berger, E. A. & Burastero, S. E. (2005). Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains. J Virol 79, 6957-6968.
13. Madani, N., Schö n, A., Princiotto, A. M., Lalonde, J. M., Courter, J. R., Soeta, T., Ng, D., Wang, L., Brower, E. T. & other authors (2008). Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. Structure 16, 1689-1701.
14. Mascola, J. R., Stiegler, G., VanCott, T. C., Katinger, H., Carpenter, C. B., Hanson, C. E., Beary, H., Hayes, D., Frankel, S. S. & other authors (2000). Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6, 207-210.
15. Moore, J. P., Cao, Y., Qing, L., Sattentau, Q. J., Pyati, J., Koduri, R., Robinson, J., Barbas, C. F., III, Burton, D. R. & Ho, D. D. (1995). Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J Virol 69, 101-109.
16. Narumi, T., Ochiai, C., Yoshimura, K., Harada, S., Tanaka, T., Nomura, W., Arai, H., Ozaki, T., Ohashi, N. & other authors (2010). CD4 mimics targeting the HIV entry mechanism and their hybrid molecules with a CXCR4 antagonist. Bioorg Med Chem Lett 20, 5853-5858.
17. Narumi, T., Arai, H., Yoshimura, K., Harada, S., Nomura, W., Matsushita, S. & Tamamura, H. (2011). Small molecular CD4 mimics as HIV entry inhibitors. Bioorg Med Chem 19, 6735-6742.
18. Narumi, T., Arai, H., Yoshimura, K., Harada, S., Hirota, Y., Ohashi, N., Hashimoto, C., Nomura, W., Matsushita, S. & Tamamura, H. (2013). CD4 mimics as HIV entry inhibitors: lead optimization studies of the aromatic substituents. Bioorg Med Chem 21, 2518-2526.
19. Nishimura, Y., Igarashi, T., Haigwood, N. L., Sadjadpour, R., Donau, O. K., Buckler, C., Plishka, R. J., Buckler-White, A. & Martin, M. A. (2003). Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. Proc Natl Acad Sci U S A 100, 15131-15136.
20. Nishimura, Y., Shingai, M., Willey, R., Sadjadpour, R., Lee, W. R., Brown, C. R., Brenchley, J. M., Buckler-White, A., Petros, R. & other authors (2010). Generation of the pathogenic R5-tropic simian/human immunodeficiency virus SHIVAD8 by serial passaging in rhesus macaques. J Virol 84, 4769-4781.
21. Platt, E. J., Wehrly, K., Kuhmann, S. E., Chesebro, B. & Kabat, D. (1998). Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 72, 2855-2864.
22. Shibata, R. & Adachi, A. (1992). SIV/HIV recombinants and their use in studying biological properties. AIDS Res Hum Retroviruses 8, 403-409.
23. Shimizu, Y., Okoba, M., Yamazaki, N., Goto, Y., Miura, T., Hayami, M., Hoshino, H. & Haga, T. (2006). Construction and in vitro characterization of a chimeric simian and human immunodeficiency virus with the RANTES gene. Microbes Infect 8, 105-113.
24. Shinohara, K., Sakai, K., Ando, S., Ami, Y., Yoshino, N., Takahashi, E., Someya, K., Suzaki, Y., Nakasone, T. & other authors (1999). A highly pathogenic simian/human immunodeficiency virus with genetic changes in cynomolgus monkey. J Gen Virol 80, 1231-1240.
25. Thali, M., Moore, J. P., Furman, C., Charles, M., Ho, D. D., Robinson, J. & Sodroski, J. (1993). Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol 67, 3978-3988.
26. von Brunn, A., Brand, M., Reichhuber, C., Morys-Wortmann, C., Deinhardt, F. & Schö del, F. (1993). Principal neutralizing domain of HIV-1 is highly immunogenic when expressed on the surface of hepatitis B core particles. Vaccine 11, 817-824.
27. Wei, X., Decker, J. M., Liu, H., Zhang, Z., Arani, R. B., Kilby, J. M., Saag, M. S., Wu, X., Shaw, G. M. & Kappes, J. C. (2002). Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46, 1896-1905.
28. Wyatt, R., Kwong, P. D., Desjardins, E., Sweet, R. W., Robinson, J., Hendrickson, W. A. & Sodroski, J. G. (1998). The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393, 705-711.
29. Yamada, Y., Ochiai, C., Yoshimura, K., Tanaka, T., Ohashi, N., Narumi, T., Nomura, W., Harada, S., Matsushita, S. & Tamamura, H. (2010). CD4 mimics targeting the mechanism of HIV entry. Bioorg Med Chem Lett 20, 354-358.
30. Yoshimura, K., Harada, S., Shibata, J., Hatada, M., Yamada, Y., Ochiai, C., Tamamura, H. & Matsushita, S. (2010). Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds. J Virol 84, 7558-7568.
31. Yusa, K., Maeda, Y., Fujioka, A., Monde, K. & Harada, S. (2005). Isolation of TAK-779-resistant HIV-1 from an R5 HIV-1 GP120 V3 loop library. J Biol Chem 280, 30083-30090.
32. Zhao, Q., Ma, L., Jiang, S., Lu, H., Liu, S., He, Y., Strick, N., Neamati, N. & Debnath, A. K. (2005). Identification of N-phenyl-N9-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology 339, 213-225.